Anti-malarial activity of a non-piperidine library of next-generation quinoline methanols

Malaria Journal

Volumn 9, Issue 1, 2010, Pages

  Milner, Erin ^a   McCalmont, William ^a   Bhonsle, Jayendra ^a   Caridha, Diana ^a   Cobar, Jose ^a   Gardner, Sean ^a   Gerena, Lucia ^a   Goodine, Duane ^a   Lanteri, Charlotte ^a   Melendez, Victor ^a   Roncal, Norma ^a   Sousa, Jason ^a   Wipf, Peter ^b   Dow, Geoffrey Stuart ^a  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMINE; MEFLOQUINE; QUINOLINE DERIVATIVE; UNCLASSIFIED DRUG; WR 176990; WR 177000; WR 183544; WR 308245; WR 308248; WR 308249; WR 308253; WR 308254; WR 308255; WR 308257; WR 308266; WR 308277; WR 308278; WR 308375; WR 308387; WR 308388; WR 308396; WR 308413; WR 308446; WR 308485; WR 308486; WR 308491; WR 308592; WR 308628; ANTIMALARIAL AGENT; HYPOXANTHINE; METHANOL; QUINOLINE;

ANIMAL CELL; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG STRUCTURE; DRUG SYNTHESIS; HYDROGEN BOND; IN VITRO STUDY; MOLECULAR WEIGHT; NONHUMAN; PHYSICAL CHEMISTRY; PLASMODIUM FALCIPARUM; DRUG DEVELOPMENT; DRUG EFFECT; PERMEABILITY;

ANTIMALARIALS; DRUG DISCOVERY; HYPOXANTHINE; MEFLOQUINE; METHANOL; PERMEABILITY; PLASMODIUM FALCIPARUM; QUINOLINES;

EID: 77949285672     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-9-51     Document Type: Article

References (22)

1. Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki. GS Dow AJ Magill C Ohrt, Ther Clin Risk Manag 2008 4 19209263
2. The IPTi Consortium: research for policy and action. D Schellenberg B Cisse C Mendendez, Trends Parasitol 2006 22 296 300 10.1016/j.pt.2006.05.006 16713739
3. Drug-free holidays: pre-travel versus during travel malaria chemoprophylaxis. GD Shanks AJ Magill DO Freedman JS Keystone DJ Bradley R Steffen, Am J Trop Med Hyg 2007 77 1 2 17620622
4. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. P Rendi-Wagner H Noedl WH Wernsdorfer G Weidermann A Mikolasek H Kollaristch, Acta Trop 2002 81 167 173 10.1016/S0001-706X(01)00210-8 11801224
5. Mefloquine-induced disruption of calcium homeostasis in mammalian cells is similar to that induced by ionomycin. A Caridha D Yourick M Cabezas L Wolf TH Hudson GS Dow, Antimicrob Agent Chemother 2008 52 684 693 10.1128/AAC.00874-07
6. Mefloquine induces dose-related neurological effects in a rat model. G Dow R Bauman D Caridha M Cabezas F Du R Gomez-Lobo M Park K Smith K Cannard, Antimicrob Agent Chemother 2006 50 1045 1053 10.1128/AAC.50.3.1045-1053.2006
7. In silico prediction of blood-brain barrier permeation. DE CLARK, Drug Discov Today 2003 8 927 933 10.1016/S1359-6446(03)02827-7 14554156
8. Passive permeability and p-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. KM Doan JE Humphreys LO Webster SA Wring LL Shampine CJ Serabit-Singh KK Adkinson JW Polli, J Pharmacol Exp Therap 2002 303 1029 1037 10.1124/jpet.102.039255
9. Transport of small molecules through blood-brain barrier: biology and methodology. WM Pardridge, Adv Drug Deliv Rev 1995 15 5 36 10.1016/0169-409X(95) 00003-P
10. CNS drug design based on principles of blood-brain barrier transport. WM Pardridge, J Neurochem 1998 70 1781 1792 9572261
11. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. RN Price AC Uhleman A Brockman R McGready E Ashley L Phaipun R Patel K Laing S Looareesuwan NJ White F Nosten S Krishna, Lancet 2004 364 438 447 10.1016/S0140-6736(04)16767-6 15288742
12. Utility of alkylaminoquinolinyl methanols as new antimalarial drugs. GS Dow TN Heady AK Bhattarchargee D Caridha L Gerena M Gettayacamin CA Lanteri III Obaldia N N Roncal T Shearer PL Smith A Tungtaeng L Wolf M Cabezas D Yourick KS Smith, Antimicrob Agents Chemother 2006 50 4132 4143 10.1128/AAC.00631-06 16966402
13. Structure-activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. E Milner W McCalmont J Bhonsle C Caridha D Carroll S Gardner L Gerena M Gettayacamin C Lanteri T Luong V Melendez J Moon N Roncal J Sousa A Tangtaeng P Wipf GS Dow, Bioorg Med Chem Lett 2010 20097070
14. Drug-like properties and the causes of poor solubility and poor permeability. CA Lipinski, J Pharmacol Toxicol Methods 2000 44 235 249 10.1016/S1056-8719(00)00107-6 11274893
15. EH Kerns L Di, Drug-like properties: concepts, structure design and methods Burlington, MA, Elsevier Inc 2008 Dow GS, Chen Y, Andrews KT, Caridha D, Gerena L, Gettayacamin M, Johnson J, Li Q, Melendez V, Obaldia N III, Tran TN and Kozikowski A: Antimalarial activity of phenylthiazolyl-bearing hydroxamate-based histone deacetylase inhibitors. Antimicrob Agents Chemother 2008 52: 3467-3477.
16. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. RE Desjardins CJ Canfield JD Haynes JD Chulay, Antimicrob Agents Chemother 1979 16 710 8 394674
17. In vitro activities of and mechanisms of resistance to antifol antimalarial drugs. WK Milhous NF Weatherly JH Bowdre RE Desjardins, Antimicrob Agents Chemother 1985 27 525 30 3890727
18. Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives. JJ Gillespie DR Adams D Bebbington K Benwell IA Cliffe CF Dawson CT Dourish A Fletcher S Gaur PR Giles AM Jordan AR Knight LJ Knutsen A Lawrence J Lerpiniere A Misra RH Porter RM Pratt R Shepherd R Upton S Ward SM Weiss DS Williamson, Bioorg Med Chem Lett 2008 18 2916 2919 10.1016/j.bmcl.2008.03.075 18406614
19. Discovery of nonxanthine adenosine A2A receptor antagonists for the treatment of Parkinson's disease. SM Weiss K Benwell IA Cliffe RJ Gillespie AR Knight J Lerpiniere A Misar RM Pratt D Revell R Upton CT Dourish, Neurology 2003 61 101 106 14663021
20. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier. Q Wang JD Rager K Weinstein PS Kardos GL Dobson J Li IJ Hidalgo, Int J Pharm 2005 288 349 359 10.1016/j.ijpharm.2004.10.007 15620875
21. Thermodynamics of partitioning of the antimalarial drug mefloquine in phospholipid bilayers and bulk solvents. ML Go TL Ngiam, Chem Pharm Bull 1997 45 2055 2060 9433777
22. A nuclear magnetic resonance study of the interactions of the antimalarials chloroquine, quinacrine, quinine and mefloquine with dipalmitoylphosphatidylcholine bilayers. R Zidovetzki IW Sherman A Attiya H De Boeck, Mol Biochem Parasitol 1989 35 199 207 10.1016/0166-6851(89)90206-5 2787476